Literature DB >> 15571060

Diagnosis and management of multiple sclerosis.

Peter A Calabresi1.   

Abstract

Multiple sclerosis, an idiopathic inflammatory disease of the central nervous system, is characterized pathologically by demyelination and subsequent axonal degeneration. The disease commonly presents in young adults and affects twice as many women as men. Common presenting symptoms include numbness, weakness, visual impairment, loss of balance, dizziness, urinary bladder urgency, fatigue, and depression. The diagnosis of multiple sclerosis should be made by a physician with experience in identifying the disease. Diagnosis should be based on objective evidence of two or more neurologic signs that are localized to the brain or spinal cord and are disseminated in time and space (i.e., occur in different parts of the central nervous system at least three months apart). Magnetic resonance imaging with gadolinium contrast, especially during or following a first attack, can be helpful in providing evidence of lesions in other parts of the brain and spinal cord. A second magnetic resonance scan may be useful at least three months after the initial attack to identify new lesions and provide evidence of dissemination over time. It is critical to exclude other diseases that can mimic multiple sclerosis, including vascular disease, spinal cord compression, vitamin B12 deficiency, central nervous system infection (e.g., Lyme disease, syphilis), and other inflammatory conditions (e.g., sarcoidosis, systemic lupus erythematosus, Sjögren's syndrome). Symptom-specific drugs can relieve spasticity, bladder dysfunction, depression, and fatigue. Five disease-modifying treatments for multiple sclerosis have been approved by the U.S. Food and Drug Administration. These treatments are partially effective in reducing exacerbations and may slow progression of disability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15571060

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  49 in total

1.  Multiple sclerosis review.

Authors:  Marvin M Goldenberg
Journal:  P T       Date:  2012-03

2.  Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity.

Authors:  Erez Eitan; Emmette R Hutchison; Nigel H Greig; David Tweedie; Hasan Celik; Soumita Ghosh; Kenneth W Fishbein; Richard G Spencer; Carl Y Sasaki; Paritosh Ghosh; Soumen Das; Susheela Chigurapati; James Raymick; Sumit Sarkar; Srinivasulu Chigurupati; Sudipta Seal; Mark P Mattson
Journal:  Exp Neurol       Date:  2015-08-13       Impact factor: 5.330

Review 3.  "Dazed and diffused": making sense of diffusion abnormalities in neurologic pathologies.

Authors:  K M O'Connor; G Barest; T Moritani; O Sakai; A Mian
Journal:  Br J Radiol       Date:  2013-10-28       Impact factor: 3.039

4.  Neuropsychiatric manifestations of multiple sclerosis.

Authors:  Laura C Politte; Jeff C Huffman; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 5.  Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

Review 6.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 7.  Advancing drug delivery systems for the treatment of multiple sclerosis.

Authors:  Inna Tabansky; Mark D Messina; Catherine Bangeranye; Jeffrey Goldstein; Karen M Blitz-Shabbir; Suly Machado; Venkatesh Jeganathan; Paul Wright; Souhel Najjar; Yonghao Cao; Warren Sands; Derin B Keskin; Joel N H Stern
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

8.  Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity.

Authors:  Riccardo Torosantucci; Victor S Sharov; Miranda van Beers; Vera Brinks; Christian Schöneich; Wim Jiskoot
Journal:  Mol Pharm       Date:  2013-05-02       Impact factor: 4.939

9.  Disease-modifying therapies in relapsing-remitting multiple sclerosis.

Authors:  Fabricio González-Andrade; José Luis Alcaraz-Alvarez
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 10.  Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment.

Authors:  Richard A Rudick; Deborah M Miller
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.